GSR and colonic neoplasm: In addition, studies have shown that the combination of quercetin and oxaliplatin can synergically inhibit glutathione reductase activity in human colon cancer HCT116 cells, reduce intracellular glutathione levels, increase ROS production, and reduce cell viability.